These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519 [TBL] [Abstract][Full Text] [Related]
3. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221 [TBL] [Abstract][Full Text] [Related]
4. [Cervix carcinoma--Austrian Vaccination Committee recommends HPV vaccination]. Six L; Joura EA Wien Med Wochenschr; 2007; 157(5-6):130-2. PubMed ID: 17427010 [No Abstract] [Full Text] [Related]
5. Human papillomavirus vaccine efficacy: aligning expectations with reality. Smith-McCune KK Gynecol Oncol; 2008 Oct; 111(1):1-2. PubMed ID: 18922296 [No Abstract] [Full Text] [Related]
6. [Vaccination against HPV in adults]. Gil Á Rev Esp Quimioter; 2009 Nov; 22 Suppl 1():22-5. PubMed ID: 20084345 [No Abstract] [Full Text] [Related]
7. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in the UK. Cuzick J; Castañón A; Sasieni P Br J Cancer; 2010 Mar; 102(5):933-9. PubMed ID: 20104226 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials. Tota JE; Struyf F; Sampson JN; Gonzalez P; Ryser M; Herrero R; Schussler J; Karkada N; Rodriguez AC; Folschweiller N; Porras C; Schiffman M; Schiller JT; Quint W; Kreimer AR; Wheeler CM; Hildesheim A; J Natl Cancer Inst; 2020 Aug; 112(8):818-828. PubMed ID: 31697384 [TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus quadrivalent vaccine: a look behind the numbers. Flaherty DK; Alkhateeb FM Ann Pharmacother; 2009 Apr; 43(4):740-4. PubMed ID: 19276314 [TBL] [Abstract][Full Text] [Related]
10. [HPV vaccination and cervical cancer screening]. Sigurdsson K Laeknabladid; 2007 Dec; 93(12):819, 821. PubMed ID: 18057470 [No Abstract] [Full Text] [Related]
11. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Dillner J; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Maansson R; Lu S; Vuocolo S; Hesley TM; Saah A; Barr E; Haupt RM Cancer Prev Res (Phila); 2009 Oct; 2(10):868-78. PubMed ID: 19789295 [TBL] [Abstract][Full Text] [Related]
12. Papillomavirus vaccine types 16 and 18: new drug. Cervical cancer: just another vaccine. Prescrire Int; 2008 Jun; 17(95):103-4. PubMed ID: 18623911 [TBL] [Abstract][Full Text] [Related]
13. HPV vaccination to prevent HIV infection: time for randomized controlled trials. van der Loeff MF; Nyitray AG; Giuliano AR Sex Transm Dis; 2011 Jul; 38(7):640-3. PubMed ID: 21301387 [No Abstract] [Full Text] [Related]
14. Gynaecological cancer: HPV vaccine: is age just a number? Stone L Nat Rev Urol; 2014 Nov; 11(11):605. PubMed ID: 25245243 [No Abstract] [Full Text] [Related]
15. Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model. Usher C; Tilson L; Olsen J; Jepsen M; Walsh C; Barry M Vaccine; 2008 Oct; 26(44):5654-61. PubMed ID: 18723068 [TBL] [Abstract][Full Text] [Related]
16. [Diseases caused by human papilloma viruses]. Zollner U; Schwarz TF Dtsch Med Wochenschr; 2011 May; 136(20):1067-72. PubMed ID: 21560109 [TBL] [Abstract][Full Text] [Related]
17. Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine. Luxembourg A; Kjaer SK; Nygard M; Ellison MC; Group T; Marshall JB; Radley D; Saah A Contemp Clin Trials; 2017 Jan; 52():54-61. PubMed ID: 27777126 [TBL] [Abstract][Full Text] [Related]
18. [Human papillomavirus (HPV) vaccines--a new method for the prevention of cervical cancer]. Friedek DA; Ekiel AM; Martirosian G Wiad Lek; 2007; 60(1-2):34-8. PubMed ID: 17607966 [TBL] [Abstract][Full Text] [Related]
19. Human papilloma virus and cancer of the cervix: a challenge facing Nepal. Gilbert DC Kathmandu Univ Med J (KUMJ); 2006; 4(3):396-7. PubMed ID: 18603941 [No Abstract] [Full Text] [Related]
20. Impact of vaccination with Cervarix (trade mark) on subsequent HPV-16/18 infection and cervical disease in women 15-25 years of age. Harper DM Gynecol Oncol; 2008 Sep; 110(3 Suppl 1):S11-7. PubMed ID: 18649932 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]